Page 11 - Valuating News Today

The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for

Salt Lake City, Utah--(Newsfile Corp. - November 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today the dosing of the first patient in a first-in-human open-label

KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program

Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of

~ Announces Timing of Corporate Update Call ~SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech

Study evaluating efficacy of MODIA, a digital therapeutic, in addition to clinician supervised medication-assisted treatment programs for individuals with opioid use disorder (OUD)The study

STOCKHOLM, Oct. 19, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced Kidney International has published the successful

Helsinn publishes new data evaluating chlormethine gel's mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 - Helsinn Group ("Helsinn"), a fully integrated, global

Indian billionaire Gautam Adani-led Adani Enterprises Ltd on Friday said it was not evaluating a proposal to acquire Jaiprakash Associates Ltds cement business.... | October 14, 2022

Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless